Avid Bioservices Inc (CDMO)

[biopharm]

"approval was based on data from the HannaH study which showed that the subcutaneous formulation of Herceptin was associated with comparable efficacy (pathological complete response, pCR) "

Interesting times....as we are clearly moving into blood tests...or liquid biopsy and yes, this will end up leading to pCR Pathoogical Complete Responses....likely from those in Sunrise that we were told by Peregrine to be still on Bavituximab treatment

pCR .... and ORR ... both helping and leading to primary endpoints in future trials